Background A safe and efficacious vaccine against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …

Background The management of complex orthopedic infections usually includes a prolonged
course of intravenous antibiotic agents. We investigated whether oral antibiotic therapy is …

Sections of formalin-fixed, paraffin-embedded tissue from 185 primary breast carcinomas
were stained immunohistochemically using a polyclonal antibody against the c-erbB-2 …

We report that, in human skin, exposure to equally erythemogenic doses of UVA, UVB, and
UVC increases immunocytochemically detected p53 in a wavelength-specific pattern. UVC …

Background The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
might be curtailed by vaccination. We assessed the safety, reactogenicity, and …

Background Older adults (aged ≥70 years) are at increased risk of severe disease and
death if they develop COVID-19 and are therefore a priority for immunisation should an …

Background The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency
use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, …

Background A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of
COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy …

Background The medium-term effects of Coronavirus disease (COVID-19) on organ health,
exercise capacity, cognition, quality of life and mental health are poorly understood. Methods …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of
Coronavirus Disease 2019 (COVID-19), has caused a global pandemic, and safe, effective …